Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ICON Central Laboratories Launches New Facility In Singapore To Meet Spiking Demand

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - ICON Central Laboratories recently moved its operation in Singapore to a larger facility to keep pace with a sharp rise in demand for its lab services across Asia

You may also be interested in...



ICON Goes Local As China CRO Market Heats Up

Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.

ICON Opens New Asian Offices To Keep Pace With Growing Demand For More Trials In Emerging Markets

BEIJING - Ireland-headquartered global contract research organization ICON is expanding its presence in the Asia Pacific region due to the growing attractiveness of conducting clinical trials in the region

ICON Opens New Asian Offices To Keep Pace With Growing Demand For More Trials In Emerging Markets

BEIJING - Ireland-headquartered global contract research organization ICON is expanding its presence in the Asia Pacific region due to the growing attractiveness of conducting clinical trials in the region

Table

View full table

Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC072165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By